Free Full Text in Portugese at:
Arq Neuropsiquiatr 2002 Sep;60(3B):881-886
Lana-Peixoto MA, Callegaro D, Moreira MA, Campos GB, Marchiori PE, Gabbai AA, Bacheschi LA, Arruda WO, Gama PD, Melo AS, Rocha FC, Lino AM, Ferreira ML, Ataide L Jr.
There has been unprecedented advances in knowledge of multiple sclerosis (MS) in the last few years.
A new set of criteria for its diagnosis and a bunch of recent clinical trials with disease-modifying agents (DMA) have been published.
All of that has made it necessary to update and expand the previous consensus for MS treatment as formulated by the Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS) two years ago.
The BCTRIMS Expanded Consensus emphasizes the need to (1) consider MS treatment on an individual basis; (2) educate patients about the potential benefits and risks of treatment; (3) monitor drugs side effects; (4) have a signed Informed Consent Form; (5) consider the relative cost of the drug.
The various clinical possibilities and the indications of the DMA and other immunointerventions are considered according to classes of evidences and types of recommendations.
The BCTRIMS Expanded Consensus on Treatment of MS may turn out to be a model to other developing countries.